{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:21:40Z","timestamp":1777616500190,"version":"3.51.4"},"reference-count":43,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5582\/bst.2016.01266","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T22:09:40Z","timestamp":1484777380000},"page":"41-45","source":"Crossref","is-referenced-by-count":7,"title":["Research progress on the direct antiviral drugs for hepatitis C virus"],"prefix":"10.5582","volume":"11","author":[{"given":"Jianjun","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Qingdao University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanxia","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Qingdao University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Elsebai MF, Mocan A, Atanasov AG. Cynaropicrin: A comprehensive research review and therapeutic potential as an anti-hepatitis C virus agent. Front Pharmacol. 2016; 7:472.","DOI":"10.3389\/fphar.2016.00472"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gravitz L. Introduction: a smouldering public-health crisis. Nature. 2011; 474:S2-4.","DOI":"10.1038\/474S2a"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57:1333-1342.","DOI":"10.1002\/hep.26141"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zhou M, Li H, Ji Y, Ma Y, Hou F, Yuan P. Hepatitis C virus infection in the general population: A large community-based study in Mianyang, West China. Biosci Trends. 2015; 9:97-103.","DOI":"10.5582\/bst.2015.01033"},{"key":"5","unstructured":"5. Fact sheet of hepatitis C. World Health Organization. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ (accessed December 1, 2016)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Xia JF, Gao JJ, Inagaki Y, Kokudo N, Nakata M, Tang W. Flavonoids as potential anti-hepatocellular carcinoma agents: recent approaches using HepG2 cell line. Drug Discov Ther. 2013; 7:1-8.","DOI":"10.5582\/ddt.2013.v7.1.1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Zhong Y, Liu B, Deng M, Xu R. Adjuvant systemic drug therapy and recurrence of hepatocellular carcinoma following curative resection. Drug Discov Ther. 2013; 7:164-166.","DOI":"10.5582\/ddt.2013.v7.4.164"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Hezode C. Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions. J Viral Hepat. 2016. DOI: 10.1111\/jvh.12635.","DOI":"10.1111\/jvh.12635"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Xia J, Inagaki Y, Song P, Sawakami T, Kokudo N, Hasegawa K, Sakamoto Y, Tang W. Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus. Biosci Trends. 2016; 10:327-336.","DOI":"10.5582\/bst.2016.01110"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kaneko J, Sugawara Y, Yamaguchi T, Harada N, Akamatsu N, Ishizawa T, Aoki T, Sakamoto Y, Hasegawa K, Tamura S, Tanaka T, Kokudo N. Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients. Biosci Trends. 2014; 8:339-345.","DOI":"10.5582\/bst.2014.01101"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chen H, Yao Y, Wang Y, Zhou H, Xu T, Liu J, Wang G, Zhang Y, Chen X, Liu Q, Huang P, Yu R. Polymorphisms of HLA-DM on treatment response to interferon\/ribavirin in patients with chronic hepatitis C virus type 1 infection. Int J Environ Res Public Health. 2016; 13:E1030.","DOI":"10.3390\/ijerph13101030"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Op De Beeck A, Dubuisson J. Topology of hepatitis C virus envelope glycoproteins. Rev Med Virol. 2003; 13:233-241.","DOI":"10.1002\/rmv.391"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005; 436:933-938.","DOI":"10.1038\/nature04077"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gupta G, Qin H, Song J. Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations. PloS one. 2012; 7:e39261.","DOI":"10.1371\/journal.pone.0039261"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K. Assembly, purification, and pre-steady-state kinetic analysis of active RNA-dependent RNA polymerase elongation complex. J Biol Chem. 2012; 287:10674-10683.","DOI":"10.1074\/jbc.M111.325530"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007; 5:453-463.","DOI":"10.1038\/nrmicro1645"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rigat K, Wang Y, Hudyma TW, Ding M, Zheng X, Gentles RG, Beno BR, Gao M, Roberts SB. Ligand induced changes in hepatitis C virus NS5B polymerase structure. Antiviral Res. 2010; 88:197-206.","DOI":"10.1016\/j.antiviral.2010.08.014"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kliemann DA, Tovo CV, da Veiga AB, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol. 2016; 22:8910-8917.","DOI":"10.3748\/wjg.v22.i40.8910"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61:77-87.","DOI":"10.1002\/hep.27259"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42:962-973.","DOI":"10.1002\/hep.20819"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. McConachie SM, Wilhelm SM, Kale-Pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmacol. 2016; 9:287-302.","DOI":"10.1586\/17512433.2016.1129272"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Lee R, Kottilil S, Wilson E. Sofosbuvir\/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int. 2016. DOI: 10.1007\/s12072-016-9776-8.","DOI":"10.1007\/s12072-016-9776-8"},{"key":"23","unstructured":"23. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02607735?ter m=SOF%2FVEL%2FVOX&rank=4 (accessed December 21, 2016)."},{"key":"24","unstructured":"24. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT026392 47?term=SOF%2FVEL%2FVOX&rank=2 (accessed December 21, 2016)."},{"key":"25","unstructured":"25. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02607800?ter m=SOF%2FVEL%2FVOX&rank=3 (accessed December 21, 2016)."},{"key":"26","unstructured":"26. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02639338?ter m=SOF%2FVEL%2FVOX&rank=1 (accessed December 21, 2016)."},{"key":"27","unstructured":"27. http:\/\/investors.gilead.com\/phoenix. zhtml?c=69964&p=irol-newsArticle&ID=2213438 (accessed December 21, 2016)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol. 2011; 54:1069-1072.","DOI":"10.1016\/j.jhep.2010.11.033"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012; 56:5387-5396.","DOI":"10.1128\/AAC.01186-12"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med.2012; 366:216-224.","DOI":"10.1056\/NEJMoa1104430"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based treatment regimens for hepatitis C virus infection: A systematic review and meta-analysis. Hepat Mon. 2016; 16:e41077.","DOI":"10.5812\/hepatmon.41077"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, et al. Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline. Hepat Mon. 2016; 16:e40959.","DOI":"10.5812\/hepatmon.guideline"},{"key":"33","unstructured":"33. WHO. Guidelines approved by the Guidelines Review Committee. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. World Health Organization. 2015."},{"key":"34","unstructured":"34. Olysio (simeprevir) capsules prescribing information. Titusville, NJ; 2016."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014; 146:1669-1679 e1663.","DOI":"10.1053\/j.gastro.2014.02.051"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014; 384:414-426.","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384:1756-1765.","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"38","unstructured":"38. American Association for the Study of Liver Diseases (AASLD). Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.aasld.org\/ (accessed November 21, 2016)."},{"key":"39","unstructured":"39. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT0185260 4?term=simeprevir++samatasvir&rank=3 (accessed December 1, 2016)."},{"key":"40","doi-asserted-by":"crossref","unstructured":"41. Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, et al. Effectiveness and safety of ombitasvir-paritaprevir\/ritonavir and dasabuvir with or without ribavirin for HCV genotype 1 infection for 12 weeks under routine clinical practice. Ann Pharmacother. 2016; 50:901-908.","DOI":"10.1177\/1060028016659306"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370:1983-1992.","DOI":"10.1056\/NEJMoa1402338"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Mullhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Jr., Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147:359-365 e351.","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44. Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C. Aust Prescr. 2016; 39:141-143.","DOI":"10.18773\/austprescr.2016.045"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/11\/1\/11_2016.01266\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T18:32:26Z","timestamp":1568745146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/11\/1\/11_2016.01266\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2016.01266","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}